Literature DB >> 23941276

Endothelin-1 and endothelin-2 initiate and maintain contractile responses by different mechanisms in rat mesenteric and cerebral arteries.

M G Compeer1, G M J Janssen, J G R De Mey.   

Abstract

BACKGROUND AND
PURPOSE: Endothelin (ET)-1 and ET-2 cause potent long-lasting vasoconstrictions by tight binding to smooth muscle ETA receptors. We tested the hypotheses that different mechanisms mediate initiation and maintenance of arterial contractile responses to ET-1 and ET-2 and that this differs among vascular beds. EXPERIMENTAL APPROACH: Segments of rat mesenteric resistance artery (MRA) and basilar artery (BA) were studied in wire myographs with and without functional antagonists. KEY
RESULTS: Sensitivity and maximum of MRA contractile responses to ET-1 were not, or only moderately, reduced by stimulation of soluble GC, AC or K(+) -channels and by an inhibitor of receptor-operated ion channels. However, each of these reduced maintenance of ET-1 effects and relaxed ET-1-induced contractions in MRA. A calcium channel antagonist did not alter sensitivity, maximum and maintenance of ET-1 effects, but relaxed ET-1-induced contractions in MRA. A PLC inhibitor prevented contractile responses to ET-1 and ET-2 in MRA and BA, and relaxed ET-1- and ET-2-induced responses in MRA and ET-1 effects in BA. A Rho-kinase inhibitor did not modify sensitivity, maximum and maintenance of responses to both peptides in both arteries but relaxed ET-2, but not ET-1, effects in MRA and ET-1 effects in BA. CONCLUSIONS AND IMPLICATIONS: PLC played a key role in arterial contractile responses to ETs, but ET-1 and ET-2 initiated and maintained vasoconstriction through different mechanisms, and these differed between MRA and BA. Selective functional antagonism may be considered for agonist- and vascular bed selective pharmacotherapy of ET-related diseases.
© 2013 The British Pharmacological Society.

Entities:  

Keywords:  ETA receptors; PLC; RhoK; basilar artery; endothelin-1; endothelin-2; mesenteric resistance artery; vascular smooth muscle; vasoconstrictions; vasospasms

Mesh:

Substances:

Year:  2013        PMID: 23941276      PMCID: PMC3838695          DOI: 10.1111/bph.12332

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  60 in total

1.  Guide to Receptors and Channels (GRAC), 5th edition.

Authors:  Stephen P H Alexander; Alistair Mathie; John A Peters
Journal:  Br J Pharmacol       Date:  2011-11       Impact factor: 8.739

Review 2.  G-protein-coupled receptor allosterism: the promise and the problem(s).

Authors:  A Christopoulos; L T May; V A Avlani; P M Sexton
Journal:  Biochem Soc Trans       Date:  2004-11       Impact factor: 5.407

Review 3.  International Union of Pharmacology. XXIX. Update on endothelin receptor nomenclature.

Authors:  Anthony P Davenport
Journal:  Pharmacol Rev       Date:  2002-06       Impact factor: 25.468

4.  G-proteins are involved in contractile responses of isolated mesenteric resistance arteries to agonists.

Authors:  H C Boonen; J G De Mey
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-10       Impact factor: 3.000

5.  NADPH oxidase inhibition attenuates oxidative stress but not hypertension produced by chronic ET-1.

Authors:  Ahmed A Elmarakby; E Dabbs Loomis; Jennifer S Pollock; David M Pollock
Journal:  Hypertension       Date:  2004-12-27       Impact factor: 10.190

Review 6.  Vascular biology of endothelin signal transduction.

Authors:  C B Neylon
Journal:  Clin Exp Pharmacol Physiol       Date:  1999-02       Impact factor: 2.557

Review 7.  Clinical trials with endothelin receptor antagonists: what went wrong and where can we improve?

Authors:  Donald E Kohan; John G Cleland; Lewis J Rubin; Dan Theodorescu; Matthias Barton
Journal:  Life Sci       Date:  2012-08-06       Impact factor: 5.037

8.  Novel mechanism of endothelin-1-induced vasospasm after subarachnoid hemorrhage.

Authors:  An Xie; Yasuo Aihara; Vitali A Bouryi; Elena Nikitina; Babak S Jahromi; Zhen-Du Zhang; Masataka Takahashi; R Loch Macdonald
Journal:  J Cereb Blood Flow Metab       Date:  2007-03-28       Impact factor: 6.200

Review 9.  The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house?

Authors:  N S Kirkby; P W F Hadoke; A J Bagnall; D J Webb
Journal:  Br J Pharmacol       Date:  2007-10-29       Impact factor: 8.739

10.  Novel pyrazole compounds for pharmacological discrimination between receptor-operated and store-operated Ca(2+) entry pathways.

Authors:  H Schleifer; B Doleschal; M Lichtenegger; R Oppenrieder; I Derler; I Frischauf; T N Glasnov; C O Kappe; C Romanin; K Groschner
Journal:  Br J Pharmacol       Date:  2012-12       Impact factor: 9.473

View more
  4 in total

Review 1.  Endothelin@25 - new agonists, antagonists, inhibitors and emerging research frontiers: IUPHAR Review 12.

Authors:  J J Maguire; A P Davenport
Journal:  Br J Pharmacol       Date:  2014-11-24       Impact factor: 8.739

Review 2.  Evidence for biased agonists and antagonists at the endothelin receptors.

Authors:  Janet J Maguire
Journal:  Life Sci       Date:  2016-02-17       Impact factor: 5.037

3.  Dissecting genetic factors affecting phenylephrine infusion rates during anesthesia: a genome-wide association study employing EHR data.

Authors:  Yanfei Zhang; S Mark Poler; Jiang Li; Vida Abedi; Sarah A Pendergrass; Marc S Williams; Ming Ta Michael Lee
Journal:  BMC Med       Date:  2019-08-28       Impact factor: 8.775

Review 4.  Endothelin.

Authors:  Anthony P Davenport; Kelly A Hyndman; Neeraj Dhaun; Christopher Southan; Donald E Kohan; Jennifer S Pollock; David M Pollock; David J Webb; Janet J Maguire
Journal:  Pharmacol Rev       Date:  2016-04       Impact factor: 25.468

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.